SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ --
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or
"Sophiris"), a biopharmaceutical company studying topsalysin
(PRX302), a first-in-class, pore-forming protein, in late-stage
clinical trials for the treatment of patients with urological
diseases, today announced that Randall E. Woods, president and
chief executive officer, will present a corporate overview at the
H.C. Wainwright 21st Annual Global Investment Conference
on Monday, September 9, 2019 at
3:00 p.m. EDT in New York, NY.
The presentation will be webcast live and can be accessed
through the Investor Relations page at www.sophirisbio.com. A
replay of the presentation will be available on the Company's
website for 90 days.
About Sophiris
Sophiris Bio Inc. is a late-stage
clinical biopharmaceutical company developing topsalysin (PRX302)
for the treatment of patients with urological diseases. Topsalysin
has completed two Phase 2 clinical trials for the focal treatment
of localized prostate cancer and has completed one Phase 3 study of
topsalysin for the treatment of the lower urinary tract symptoms of
benign prostatic hyperplasia (BPH). Topsalysin is a highly potent
ablative agent that is selective and targeted in that it is only
activated by enzymatically active PSA which is found in high
concentrations in the transition zone of the prostate and in and
around prostate tumor cells. For more information, please visit
www.sophirisbio.com.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
Sophiris' current beliefs as well as assumptions made by and
information currently available to Sophiris and relate to, among
other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance
and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Sophiris in its
public securities filings; actual events may differ materially from
current expectations. Sophiris disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300909439.html
SOURCE Sophiris Bio Inc.
